Ciprofloxacin has a high in vitro activity against a broad spectrum of organisms and appears to be considerably more active against Pseudomonas aeruginosa than currently available penicillins, cephalosporins, or aminoglycosides (6, 7) . A further major advantage is that the drug is well absorbed when administered orally (1) . The major pathogen present in the sputum of adult patients with cystic fibrosis (CF) is P. aeruginosa. At present, acute infective exacerbations are treated with parenterally administered antibiotics, usually a combination of either an antipseudomonal penicillin or a cephalosporin with an aminoglycoside. Some patients also require long-term treatment with aerosol antibiotics. An oral preparation active against P. aeruginosa would be of great advantage to these patients.
Almost all patients with CF have abnormal pancreatic function with malabsorption, and absorption of some antibiotics was shown to be slower in CF patients than in controls (3) . Furthermore, the elimination of some antibiotics appears to be accelerated in CF patients (3) . The purpose of this study was, therefore, to investigate the pharmacokinetic properties of ciprofloxacin after oral administration in young adults with CF and to determine the penetration of the antibiotic into sputum.
Eight adults with CF who were chronically infected with P. aeruginosa and who required hospital admission for intensive therapy were studied. There were four males and four females, with a mean age of 24.3 years (range, 18 to 30 years). Their Ciprofloxacin concentrations in serum and sputum were assayed by high-performance liquid chromatography by using a slightly modified version of the method described by Gau et al. (2) . The limit of sensitivity was 0.05 mg/liter, and in our laboratory, the coefficients of variation were less than The mean concentrations of ciprofloxacin in the serum and sputum of the CF patients are shown in Fig. 1 . The pharmacokinetic data are summarized in Table 1 . The mean Cmax of ciprofloxacin in serum ± the standard deviation was 3.16 ± 1.27 mg/liter (range, 1.49 to 8.04 mg/liter), and the mean Tmax was 1.5 ± 0.9 h. The mean trough level at time 0 (on day 3 of therapy) was 0.64 ± 0.35 mg/liter. Peak concentrations in sputum occurred at a mean of 2.0 ± 1.0 h after the dose was administered and were approximately 30% of those obtained in serum (mean 1.01 mg/liter compared with 3.16 mg/liter in serum), and the mean ratio of the sputum-serum AUC was 0.46 ± 0.11. There was a significant correlation between ciprofloxacin levels in serum and sputum (r = 0.621, P < 0.05). The mean t1i2, of ciprofloxacin in serum was 3.6 ± 0.9 h. AUCs in serum (mean, 10.90 ± 3.33 mg. h/liter) were reasonably consistent. AUCs in sputum ranged from 3.08 to 7.43 mg h/liter.
A previous study of ciprofloxacin pharmacokinetics for normal subjects demonstrated that the drug was rapidly absorbed after oral administration and that levels in serum well above the MICs for Enterobacteriaceae, Haemophilus influenzae, P. aeruginosa, and Staphylococcus aureus could be achieved after a single dose of 500 mg (1) .
The results of the present study confirm that ciprofloxacin is also well absorbed in CF patients, and the mean Cmax in serum of 3. , 14th ICC) . However, this may in part be due to a greater variation in AUCs in the normal subjects. Tm,, for the CF patients was slightly later than that found for normal subjects (1.5 + 0.9 and 1.04 + 0.42 h, respectively [Le Bel et al., 14th ICC]). Furthermore, the mean serum t1i/2 of 3.6 ± 0.9 h for the CF patients was very similar to that found for normal subjects (3.9 ± 0.8) (1).
The MIC for 90% of the P. aeruginosa strains (MIC90) of ciprofloxacin was shown in several studies to be around 0.25 mg/liter. (6, 7 were achieved for all patients. This is in striking contrast to many other antibiotics used in the treatment of P. aeruginosa infection in CF patients. For instance, studies of levels of gentamicin, carbenicillin, azlocillin, and ticarcillin in sputum after intravenous administration show relatively poor penetration into sputum, with levels well below the MIC for P. aeruginosa (4, 5) . For four of the eight patients, levels of ciprofloxacin in sputum fell below 0.25 mg/liter after 7 h. In view of this, it may be that larger or more frequent doses should be considered in pulmonary infections if levels in sputum consistently above the MIC90 are desired.
As already stated, P. aeruginosa is by far the most common pathogen encountered in the sputum of adult patients with CF. Two other organisms, S. aureus and H. influenzae, are also encountered very frequently. Ciprofloxacin was shown to have high in vitro bactericidal activity against both of these organisms, with reported MIC9os of 0.5 mg/liter and <0.25 mg/liter, respectively.
There are a number of reasons, therefore, why ciprofloxacin may theoretically be a very useful antibiotic in the treatment of pulmonary infections in CF patients. The results of this study show that the drug is well absorbed in CF patients and has good penetration into the sputum. There is a need for further clinical trials to establish whether ciprofloxacin is a possible alternative to conventional parenteral or aerosol antipseudomonal therapy.
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